ATE367441T1 - Lipophile derivate doppelsträngiger ribonukleinsäure - Google Patents
Lipophile derivate doppelsträngiger ribonukleinsäureInfo
- Publication number
- ATE367441T1 ATE367441T1 AT04704041T AT04704041T ATE367441T1 AT E367441 T1 ATE367441 T1 AT E367441T1 AT 04704041 T AT04704041 T AT 04704041T AT 04704041 T AT04704041 T AT 04704041T AT E367441 T1 ATE367441 T1 AT E367441T1
- Authority
- AT
- Austria
- Prior art keywords
- double stranded
- ribonucleic acid
- stranded ribonucleic
- lipophilic derivatives
- lipophilic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10302421A DE10302421A1 (de) | 2003-01-21 | 2003-01-21 | Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE367441T1 true ATE367441T1 (de) | 2007-08-15 |
Family
ID=32602867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04704041T ATE367441T1 (de) | 2003-01-21 | 2004-01-21 | Lipophile derivate doppelsträngiger ribonukleinsäure |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060178324A1 (de) |
| EP (2) | EP1587926B1 (de) |
| AT (1) | ATE367441T1 (de) |
| AU (2) | AU2004206255B2 (de) |
| CA (1) | CA2513809C (de) |
| DE (2) | DE10302421A1 (de) |
| DK (1) | DK1587926T3 (de) |
| ES (1) | ES2289474T3 (de) |
| PT (1) | PT1587926E (de) |
| WO (1) | WO2004065601A2 (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| CA2884658A1 (en) | 2002-07-26 | 2004-02-05 | Novartis Vaccines And Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| EP2664672A1 (de) | 2003-04-17 | 2013-11-20 | Alnylam Pharmaceuticals Inc. | Modifizierte iRNA-Wirkstoffe |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| US8796436B2 (en) | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
| WO2005027980A1 (en) | 2003-09-12 | 2005-03-31 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
| EP2899278A1 (de) | 2004-03-12 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | iRNS-Wirkstoffe für VEGF-Targeting |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| EP2145957B1 (de) * | 2004-04-20 | 2013-12-25 | Marina Biotech, Inc. | Zusammensetzungen zur Erhöhung der Abgabe von doppelsträngiger DNA zur Regulierung der Genexpression in Säugetierzellen |
| US8138161B2 (en) * | 2004-10-01 | 2012-03-20 | Novartis Vaccines And Diagnostics, Inc. | Modified small interfering RNA molecules and methods of use |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| ATE514776T1 (de) | 2004-10-05 | 2011-07-15 | California Inst Of Techn | Aptamer-regulierte nukleinsäuren und verwendungen davon |
| US7923206B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
| US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
| US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
| AU2006279280A1 (en) | 2005-08-18 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating neurological disease |
| US8093369B2 (en) * | 2005-10-11 | 2012-01-10 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | Compositions for silencing the expression of VDAC1 and uses thereof |
| WO2007051045A2 (en) | 2005-10-28 | 2007-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
| ATE510545T1 (de) | 2005-11-09 | 2011-06-15 | Alnylam Pharmaceuticals Inc | Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen |
| RU2008141977A (ru) | 2006-03-24 | 2010-05-27 | Новартис АГ (CH) | КОМПОЗИЦИИ dsPHK И СПОСОБЫ ЛЕЧЕНИЯ HPV-ИНФЕКЦИИ |
| WO2007115168A2 (en) | 2006-03-31 | 2007-10-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 gene |
| SG171676A1 (en) | 2006-05-11 | 2011-06-29 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the pcsk9 gene |
| US7812150B2 (en) | 2006-05-19 | 2010-10-12 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of Aha and therapeutic uses thereof |
| WO2007137220A2 (en) | 2006-05-22 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of ikk-b gene |
| US8252755B2 (en) | 2006-09-22 | 2012-08-28 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| WO2008058291A2 (en) | 2006-11-09 | 2008-05-15 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
| PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
| AP3018A (en) | 2007-03-29 | 2014-10-31 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expressionof a gene from the ebola |
| WO2008131419A2 (en) | 2007-04-23 | 2008-10-30 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| EP2316943B1 (de) | 2007-07-05 | 2013-06-19 | Novartis AG | DSRNA zur Behandlung viraler Infektionen |
| US20120165387A1 (en) | 2007-08-28 | 2012-06-28 | Smolke Christina D | General composition framework for ligand-controlled RNA regulatory systems |
| US8367815B2 (en) | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
| US8865667B2 (en) | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
| TW200927177A (en) * | 2007-10-24 | 2009-07-01 | Nat Inst Of Advanced Ind Scien | Lipid-modified double-stranded RNA having potent RNA interference effect |
| AU2008335202A1 (en) | 2007-12-10 | 2009-06-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Factor VII gene |
| US9029524B2 (en) | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| WO2009102427A2 (en) | 2008-02-11 | 2009-08-20 | Rxi Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
| SG188121A1 (en) * | 2008-03-05 | 2013-03-28 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of eg5 and vegf genes |
| EP2105145A1 (de) | 2008-03-27 | 2009-09-30 | ETH Zürich | Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide |
| RU2501859C2 (ru) * | 2008-03-31 | 2013-12-20 | Нэшнл Инститьют Оф Эдванст Индастриал Сайенс Энд Текнолоджи | Модифицированная липидами двухцепочечная рнк, обладающая мощным эффектом рнк-интерференции |
| WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
| EP3208337A1 (de) | 2008-09-02 | 2017-08-23 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6 |
| WO2010033248A2 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
| EP3584320A1 (de) | 2008-09-25 | 2019-12-25 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression |
| DK2344639T3 (en) | 2008-10-20 | 2015-07-27 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETINE |
| US20120016006A1 (en) * | 2008-11-17 | 2012-01-19 | Alnylam Pharmaceuticals ,Inc. a corporation | Compositions And Methods For Increasing Cellular Uptake Of RNAi Via SID-1 |
| US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
| CA2746514C (en) | 2008-12-10 | 2018-11-27 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| WO2010099341A1 (en) | 2009-02-26 | 2010-09-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of mig-12 gene |
| US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
| WO2010129672A1 (en) | 2009-05-05 | 2010-11-11 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
| KR20120050429A (ko) | 2009-06-15 | 2012-05-18 | 알닐람 파마슈티칼스 인코포레이티드 | Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ |
| WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
| GB0910723D0 (en) | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
| AP3574A (en) | 2009-08-14 | 2016-02-08 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| WO2011034798A1 (en) | 2009-09-15 | 2011-03-24 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| KR101852210B1 (ko) | 2010-03-24 | 2018-04-25 | 알엑스아이 파마슈티칼스 코포레이션 | 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭 |
| CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
| ES2893199T3 (es) | 2010-03-29 | 2022-02-08 | Alnylam Pharmaceuticals Inc | Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR) |
| WO2012064824A1 (en) | 2010-11-09 | 2012-05-18 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| AU2013288738A1 (en) | 2012-07-10 | 2015-01-29 | Baseclick Gmbh | Anandamide-modified nucleic acid molecules |
| BR112015013105B1 (pt) | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| DE102013003869B4 (de) * | 2013-02-27 | 2016-11-24 | Friedrich-Schiller-Universität Jena | Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung |
| WO2015084897A2 (en) | 2013-12-02 | 2015-06-11 | Mirimmune, Llc | Immunotherapy of cancer |
| CN105960265A (zh) | 2013-12-04 | 2016-09-21 | 阿克赛医药公司 | 利用经化学修饰的寡核苷酸处理伤口愈合的方法 |
| WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
| US20170051290A1 (en) | 2014-05-01 | 2017-02-23 | Rxi Pharmaceuticals Corporation | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| KR20180026739A (ko) | 2015-07-06 | 2018-03-13 | 알엑스아이 파마슈티칼스 코포레이션 | 슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자 |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| US20170153257A1 (en) * | 2015-10-09 | 2017-06-01 | Dice Molecules Sv, Llc | Methods of estimating logd of tagged combinatorial library compounds |
| JP2018531037A (ja) | 2015-10-19 | 2018-10-25 | アールエックスアイ ファーマシューティカルズ コーポレーション | 長い非コードｒｎａを標的とする減少したサイズの自己送達型核酸化合物 |
| US20200123499A1 (en) | 2015-12-02 | 2020-04-23 | Massachusetts Institute Of Technology | Method for efficient generation of neurons from non-neuronal cells |
| WO2018195355A1 (en) | 2017-04-19 | 2018-10-25 | Rxi Pharmaceuticals Corporation | Topical delivery of nucleic acid compounds |
| US20230002766A1 (en) | 2019-11-08 | 2023-01-05 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy |
| EP4085136A1 (de) | 2019-12-31 | 2022-11-09 | Phio Pharmaceuticals Corp. | Chemisch modifizierte oligonukleotide mit verbesserter systemischer abgabe |
| WO2022232343A1 (en) * | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
| EP4381070A2 (de) | 2021-08-04 | 2024-06-12 | Phio Pharmaceuticals Corp. | Chemisch modifizierte oligonukleotide |
| WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
| CN115707710B (zh) * | 2021-08-18 | 2025-06-06 | 中国科学院上海有机化学研究所 | 样品衍生化试剂及其在检测旋光异构体中的应用 |
| WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0228458B2 (de) * | 1985-07-05 | 1997-10-22 | Whitehead Institute For Biomedical Research | Expression von fremdem genetischem material in epithelzellen |
| US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US6395492B1 (en) * | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6054299A (en) * | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
| US6111085A (en) * | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
| DE10160151A1 (de) * | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| WO2002026867A2 (en) * | 2000-09-29 | 2002-04-04 | The Regents Of The University Of California | Dendrimeric support or carrier macromolecule |
| US10590418B2 (en) * | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| CA2884658A1 (en) * | 2002-07-26 | 2004-02-05 | Novartis Vaccines And Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| ATE513843T1 (de) * | 2002-09-25 | 2011-07-15 | Univ Massachusetts | Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna |
| US20040147027A1 (en) * | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
-
2003
- 2003-01-21 DE DE10302421A patent/DE10302421A1/de not_active Withdrawn
-
2004
- 2004-01-21 DE DE602004007620T patent/DE602004007620T2/de not_active Expired - Lifetime
- 2004-01-21 ES ES04704041T patent/ES2289474T3/es not_active Expired - Lifetime
- 2004-01-21 EP EP04704041A patent/EP1587926B1/de not_active Expired - Lifetime
- 2004-01-21 US US10/543,048 patent/US20060178324A1/en not_active Abandoned
- 2004-01-21 DK DK04704041T patent/DK1587926T3/da active
- 2004-01-21 AU AU2004206255A patent/AU2004206255B2/en not_active Expired
- 2004-01-21 EP EP07010839A patent/EP1852506A3/de not_active Withdrawn
- 2004-01-21 AT AT04704041T patent/ATE367441T1/de active
- 2004-01-21 CA CA002513809A patent/CA2513809C/en not_active Expired - Lifetime
- 2004-01-21 PT PT04704041T patent/PT1587926E/pt unknown
- 2004-01-21 WO PCT/US2004/001461 patent/WO2004065601A2/en not_active Ceased
-
2008
- 2008-08-07 AU AU2008203538A patent/AU2008203538B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004206255B2 (en) | 2008-05-08 |
| DE10302421A1 (de) | 2004-07-29 |
| EP1587926B1 (de) | 2007-07-18 |
| CA2513809A1 (en) | 2004-08-05 |
| EP1852506A3 (de) | 2011-08-31 |
| DE602004007620T2 (de) | 2008-04-10 |
| CA2513809C (en) | 2009-10-06 |
| WO2004065601A2 (en) | 2004-08-05 |
| AU2004206255A1 (en) | 2004-08-05 |
| EP1852506A2 (de) | 2007-11-07 |
| DE602004007620D1 (de) | 2007-08-30 |
| EP1587926A2 (de) | 2005-10-26 |
| WO2004065601A3 (en) | 2004-11-18 |
| AU2008203538A1 (en) | 2008-08-28 |
| PT1587926E (pt) | 2007-10-26 |
| DK1587926T3 (da) | 2007-11-19 |
| AU2008203538B2 (en) | 2012-05-17 |
| ES2289474T3 (es) | 2008-02-01 |
| US20060178324A1 (en) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE367441T1 (de) | Lipophile derivate doppelsträngiger ribonukleinsäure | |
| SI2258847T1 (sl) | Nadaljnje nove oblike molekul interferenčne RNA | |
| EP2821085A3 (de) | RNA-Interferenz zur Behandlung von Funktionszunahmestörungen | |
| US10597719B2 (en) | Detection kit and simple method for detecting target nucleic acids | |
| BR9913360A (pt) | Oxidase de urato | |
| EP1633302A4 (de) | Modulation der apolipoprotein (a) expression | |
| BRPI0413323A (pt) | processo para a preparação de vacinas conjugadas de polissacarìdeo-proteìna | |
| WO2002026967A3 (en) | Targeted gene correction by single-stranded oligodeoxynucleotides | |
| EP1225234A3 (de) | Synthese von Nukleinsäuren | |
| DE60231543D1 (de) | Multiplex-oligonukleotidaddition und zielamplifikation | |
| BR0312121A (pt) | xinalases, ácidos nucléicos codificando-as e métodos para preparar e empregá-las | |
| CY1106752T1 (el) | Διϋδροπτεριδινονες, μεθοδος για την παραγωγη τους και χρηση τους ως φαρμακων | |
| AU2003273336A8 (en) | Efficient reduction of target rna's by single- and double-stranded oligomeric compounds | |
| ATE550427T1 (de) | Modifikationen von rna, die zu einer erhöhten transkriptstabilität und translationseffizienz führen | |
| CO5721010A2 (es) | Compuestos derivados de la deshidrofenilahistina, su metodo sintetico de preparacion y sus composiciones farmaceuticas | |
| MY150408A (en) | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-ß-D-RIBOFURANOSYL)-3H-THIAZOLE[4,5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | |
| EP1182267A4 (de) | Verfahren zur bestimmung der basensequenz eines einzelnen nukleinsäuremoleküls | |
| ATE461934T1 (de) | Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren | |
| EP1333089A4 (de) | Verfahren zur synthese einzelsträngiger nukleinsäure | |
| FR2790005B1 (fr) | Procede de fabrication de morpholino-nucleotides, et utilisation de ceux-ci pour l'analyse et le marquage de sequences d'acides nucleiques | |
| WO2007017510A3 (de) | Isophthalsäurediamide zur behandlung der alzheimer erkrankung | |
| WO2006105339A3 (en) | Gene synthesis using pooled dna | |
| EP1669458A4 (de) | Verfahren zur herstellung von 1,4-dihydroxy-2-naphthonsäure | |
| WO2001051518A3 (en) | Nucleic acids encoding human semaphorin proteins and use thereof | |
| WO2005042446A3 (de) | Verfahren zur herstellung von phytofluen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1587926 Country of ref document: EP |